GlassScriptPhysician profile
Jeffrey Hart
NPI 1770841967
$7,575.23
in general payments reported to CMS, 2019-2025
44 companies · $960 in 2025
The $960 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $582 · 2020: $615 · 2021: $1,354 · 2022: $1,256 · 2023: $1,411 · 2024: $1,397 · 2025: $960.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,743 · Education: $24.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,742.81 |
| Education | $24.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $907.57 | 2020-2025 | |
| Novo Nordisk INC | $860.70 | 2019-2025 | Rybelsus, Ozempic |
| Pfizer INC. | $699.87 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $671.76 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $487.30 | 2021-2025 | |
| Glaxosmithkline, LLC. | $436.09 | 2019-2024 | Shingrix, Arexvy |
| Novartis Pharmaceuticals Corporation | $409.38 | 2019-2025 | |
| Astellas Pharma US INC | $350.14 | 2020-2024 | Veozah, Myrbetriq |
| Amgen INC. | $305.70 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $283.06 | 2019-2025 | Belsomra, Steglujan, Steglatro |
| Amarin Pharma, INC. | $273.35 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $271.59 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $264.55 | 2020-2025 | Mounjaro, Trulicity, Jardiance |
| Daiichi Sankyo INC. | $187.11 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $118.87 | 2024-2025 | Voquezna |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Hart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.